Anavex Life Sciences Corp (AVXL)

[nidan7500]

Noted ref. PDD trial comments during 12/18 concall xstript:

And we have currently 1 million patients in the U.S. alone with Parkinson's disease, and that number is obviously much larger around the world. So this is the -- addressing the first question. The -- I'd like also to add to that, that ANAVEX 2-73 has demonstrated, in an animal model of Parkinsonian disease modification model, which was a 6-OHDA model, which is a very difficult model to have improvement in, where the animals are getting eradicated their dopaminergic region with a chemical, and then hence are impaired with motor impairment, with significant motor impairment. ANAVEX 2-73 treatment in these animals was able to a certain extent restore or ameliorate the movement impairment. So we are now also looking in our study for the signal on motor impairment as a secondary endpoint. So we try to basically address the cognitive decline feature which is reaching almost 80% of all Parkinsonian patients. And also in parallel to that, however, also the motor impairment. So that is important to appreciate in this study. The second question regarding to the ATM. So the ATM stands for at-the-market facility. We have a at-the-market facility set up which we have not yet used to date. And we will not yet -- we have no plans yet to use it. And it's really a facility for emergency or if the opportunity arises that we might utilize it. But right now, we have no plans to utilizing it as we speak since we have sufficient cash available right now in our -- on our balance sheet.

IMHO, this trial is intended to demonstrate the effects of A2-73 in BOTH motion and cognition endpoints. He chose to run a trial which has some end point metric more easily defined and measured while simultaneously studying cognitive changes, something more obtuse and difficult to measure. Now THAT"S a trial.